{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:28:59Z","timestamp":1774949339928,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.lungcan.2023.107383","type":"journal-article","created":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T19:19:44Z","timestamp":1695496784000},"page":"107383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy"],"prefix":"10.1016","volume":"186","author":[{"given":"Ibiayi","family":"Dagogo-Jack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesli A.","family":"Kiedrowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen K.","family":"Lennerz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.107383_b0005","doi-asserted-by":"crossref","unstructured":"Dagogo-Jack I, Yoda S, Lennerz JK, et al. MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clin Cancer Res. Feb 2020;10.1158\/1078-0432.CCR-19-3906.","DOI":"10.1158\/1078-0432.CCR-19-3906"},{"key":"10.1016\/j.lungcan.2023.107383_b0010","doi-asserted-by":"crossref","unstructured":"Dagogo-Jack I. Efficacy and Tolerability of ALK\/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis. 2023.","DOI":"10.1016\/j.jtocrr.2023.100534"},{"key":"10.1016\/j.lungcan.2023.107383_b0015","doi-asserted-by":"crossref","unstructured":"Piotrowska Z, Isozaki H, Lennerz JK, et al. Landscape of Acquired Resistance to Osimertinib in. Cancer Discov. 12 2018;8(12):1529-1539. 10.1158\/2159-8290.CD-18-1022.","DOI":"10.1158\/2159-8290.CD-18-1022"},{"key":"10.1016\/j.lungcan.2023.107383_b0020","doi-asserted-by":"crossref","unstructured":"Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. Apr 15 2013;19(8):2240-7. 10.1158\/1078-0432.ccr-12-2246.","DOI":"10.1158\/1078-0432.CCR-12-2246"},{"key":"10.1016\/j.lungcan.2023.107383_b0025","unstructured":"LV S, MJ A, JS L, et al. TATTON Phase Ib expansion cohort: osimertinib plus Savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on prior epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKI). Annual meeting of the American Association for Cancer Research, Atlanta, GA 2019.2019."},{"key":"10.1016\/j.lungcan.2023.107383_b0030","unstructured":"Mazieres J. LBA52 - Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study. 202."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2023.107383_b0035","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/JCO.2019.37.15_suppl.9004","article-title":"Capmatinib (INC280) in MET\u0394ex14 -mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study","volume":"37","author":"Wolf","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107383_b0040","doi-asserted-by":"crossref","unstructured":"Camidge D, GA O, Clark J, et al. Crizotinib in patients with MET-amplified non-small cell lung cancer: Updated safety and efficacy findings from a phase 1 trial. J. Clin. Oncol. 2018. p. 9062.","DOI":"10.1200\/JCO.2018.36.15_suppl.9062"},{"key":"10.1016\/j.lungcan.2023.107383_b0045","doi-asserted-by":"crossref","unstructured":"Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. Jun 10 2016;7:11815. 10.1038\/ncomms11815.","DOI":"10.1038\/ncomms11815"},{"issue":"11","key":"10.1016\/j.lungcan.2023.107383_b0050","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M\u2013Positive Lung Cancer and Acquired Resistance to Osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.lungcan.2023.107383_b0055","doi-asserted-by":"crossref","unstructured":"Odegaard JI, Vincent JJ, Mortimer S, et al. Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies. Clin Cancer Res. Aug 2018;24(15):3539-3549. 10.1158\/1078-0432.CCR-17-3831.","DOI":"10.1158\/1078-0432.CCR-17-3831"},{"issue":"12","key":"10.1016\/j.lungcan.2023.107383_b0060","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nature Medicine"},{"issue":"36","key":"10.1016\/j.lungcan.2023.107383_b0065","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1200\/JCO.2011.35.4928","article-title":"MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib","volume":"29","author":"Lennerz","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2023.107383_b0070","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.lungcan.2023.107383_b0075","doi-asserted-by":"crossref","unstructured":"Gainor JF, Dardaei L, Yoda S, et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. Oct 2016;6(10):1118-1133. 10.1158\/2159-8290.cd-16-0596.","DOI":"10.1158\/2159-8290.CD-16-0596"},{"issue":"22","key":"10.1016\/j.lungcan.2023.107383_b0080","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1158\/1078-0432.CCR-19-1436","article-title":"Treatment with Next-Generation ALK Inhibitors Fuels Plasma","volume":"25","author":"Dagogo-Jack","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107383_b0085","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK -Positive Lung Cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2023.107383_b0090","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.lungcan.2023.107383_b0095","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.18.00177","article-title":"Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer","volume":"37","author":"Lai","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107383_b0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/path.5110","article-title":"Genetic instability and recurrent MYC amplification in ALK\u2010 translocated NSCLC: a central role of TP53 mutations","volume":"246","author":"Alidousty","year":"2018","journal-title":"J. Pathol."},{"key":"10.1016\/j.lungcan.2023.107383_b0105","doi-asserted-by":"crossref","unstructured":"Tanimoto A, Matsumoto S, Takeuchi S, et al. Proteasome Inhibition Overcomes ALK-TKI Resistance in. Clin. Cancer Res. 03 01 2021;27(5):1410-1420. 10.1158\/1078-0432.CCR-20-2853.","DOI":"10.1158\/1078-0432.CCR-20-2853"},{"issue":"12","key":"10.1016\/j.lungcan.2023.107383_b0110","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib Versus Crizotinib in ALK Inhibitor\u2013Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2023.107383_b0115","doi-asserted-by":"crossref","unstructured":"Yu HA, Suzawa K, Jordan E, et al. Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clin Cancer Res. 07 01 2018;24(13):3108-3118. 10.1158\/1078-0432.CCR-17-2961.","DOI":"10.1158\/1078-0432.CCR-17-2961"},{"key":"10.1016\/j.lungcan.2023.107383_b0120","doi-asserted-by":"crossref","unstructured":"Le X. Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-levelMETamplification (METamp) detected by liquid biopsy (LBx). 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.9121"},{"issue":"5","key":"10.1016\/j.lungcan.2023.107383_b0125","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/JTO.0000000000000145","article-title":"High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer","volume":"9","author":"Feng","year":"2014","journal-title":"J. Thor. Oncol."},{"key":"10.1016\/j.lungcan.2023.107383_b0130","doi-asserted-by":"crossref","unstructured":"Besse B. Predictive biomarkers for treatment with amivantamab plus lazertinib amongEGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS. 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.9013"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223009212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223009212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:04:38Z","timestamp":1759237478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223009212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":26,"alternative-id":["S0169500223009212"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107383","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107383"}}